Microparticle-Enabled Local Sustained Delivery of Paroxetine for Osteoarthritis Treatment.
Kim Jung Hwan JH, Haj Shehadeh Tarek T, Ataie Zaman Z, Jaberi Arian A et al.
Osteoarthritis (OA) is a prevalent joint disease characterized by irreversible cartilage degradation, chronic pain, and reduced quality of life. Current treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are largely palliative, ineffective for some patients, and associated with adverse effects. We have shown that paroxetine (Px), an FDA-approved antidepressant, has potential as a disease-modifying OA drug by inhibiting the G protein-coupled receptor kinase 2 (GRK2). Elevated GRK2 activity drives inflammation, extracellular matrix degradation and cartilage damage in OA. By inhibiting GRK2, Px suppresses cartilage degeneration, enhances chondrocyte anabolic activity, and reduces inflammation in the OA joint. In this study, we develop a local, slow-release drug delivery system that harnesses the therapeutic benefits of Px for OA treatment via microfluidic-assisted encapsulation in size-controlled poly(lactic-co-glycolic acid) (PLGA) microparticles (MP). In vitro studies show that the drug release profile is controlled by tuning the MP fabrication parameters. Efficacy testing shows that Px-eluting PLGA microparticles (MP-Px) decrease fibroblast cell migration and proliferation in vitro. In vivo, the intra-articular implantation of MP-Px in the clinically relevant destabilization of medial meniscus mouse OA model decreases chondrocyte apoptosis and has some anti-inflammatory effects in the acute phase of OA. Safranin O staining indicates mild staining loss in MP-treated groups, warranting further assessment of cartilage-matrix safety with long-term use. Importantly, serum Px levels remain low following MP-Px treatment compared with intraperitoneally administered Px (IP-Px). To the best of our knowledge, this biomaterial provides the first local intra-articular delivery of Px. These short-term findings in mice support further preclinical evaluation of MP-Px, including its effects on the cartilage matrix and long-term efficacy.